Kinetics of citalopram in elderly patients
- PMID: 3929295
- DOI: 10.1007/BF00432209
Kinetics of citalopram in elderly patients
Abstract
The kinetics of the antidepressant drug citalopram, a specific 5-HT uptake inhibitor, has been investigated in 11 elderly patients (age 73-90) and compared to previous data from younger patients and volunteers. The recorded steady state citalopram levels of 140-545 nM after a once-daily 20-mg dose were up to four times higher than expected from data in younger patients and volunteers. The biological half-life (1.5-3.75 days) and estimated systemic clearance (0.08-0.3 1/min) also differed from data in younger individuals (1.5 days and 0.4 1/min, respectively). Clearance values generally decreased with increasing age. Drug/metabolite ratios were higher in patients with the longest half-lives and lowest citalopram clearance, indicating reduced metabolic activity. No reduction in renal clearance was indicated by urine data, obtained for two of the patients. The study suggests that daily doses of 5-20 mg give approximately the same steady state plasma levels in elderly patients as doses of 40 mg in younger, and that this is due to reduced rates of metabolism in the elderly.
Similar articles
-
Preliminary studies of the kinetics of citalopram in man.Eur J Clin Pharmacol. 1978 Nov 9;14(1):69-73. doi: 10.1007/BF00560260. Eur J Clin Pharmacol. 1978. PMID: 729609
-
Relationship between clinical effects, serum drug concentration and serotonin uptake inhibition in depressed patients treated with citalopram. A double-blind comparison of three dose levels.Eur J Clin Pharmacol. 1985;28(5):553-7. doi: 10.1007/BF00544066. Eur J Clin Pharmacol. 1985. PMID: 3899675 Clinical Trial.
-
The kinetics of citalopram: single and multiple dose studies in man.Acta Pharmacol Toxicol (Copenh). 1981 Jan;48(1):53-60. doi: 10.1111/j.1600-0773.1981.tb01587.x. Acta Pharmacol Toxicol (Copenh). 1981. PMID: 6939299
-
High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment.Clin Pharmacokinet. 1986 Mar-Apr;11(2):87-106. doi: 10.2165/00003088-198611020-00001. Clin Pharmacokinet. 1986. PMID: 3514045 Review.
-
Therapeutic effects of serotonin uptake inhibitors in depression.J Clin Psychiatry. 1986 Apr;47 Suppl:23-35. J Clin Psychiatry. 1986. PMID: 2937776 Review.
Cited by
-
Sertraline. A pharmacoeconomic evaluation of its use in depression.Pharmacoeconomics. 1996 Oct;10(4):409-31. doi: 10.2165/00019053-199610040-00009. Pharmacoeconomics. 1996. PMID: 10184609 Review.
-
Treatment of uncontrolled crying after stroke.Drugs Aging. 1995 Feb;6(2):105-11. doi: 10.2165/00002512-199506020-00003. Drugs Aging. 1995. PMID: 7711357 Review.
-
Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism.Clin Pharmacokinet. 1997;32 Suppl 1:1-21. doi: 10.2165/00003088-199700321-00003. Clin Pharmacokinet. 1997. PMID: 9068931 Review.
-
Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors.Clin Pharmacokinet. 1996 Dec;31(6):444-69. doi: 10.2165/00003088-199631060-00004. Clin Pharmacokinet. 1996. PMID: 8968657 Review.
-
Clinical pharmacokinetics of selective serotonin reuptake inhibitors.Clin Pharmacokinet. 1993 Mar;24(3):203-20. doi: 10.2165/00003088-199324030-00003. Clin Pharmacokinet. 1993. PMID: 8384945 Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources